Olivier Bylicki
Overview
Explore the profile of Olivier Bylicki including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
52
Citations
1019
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lena H, Greillier L, Cropet C, Bylicki O, Monnet I, Audigier-Valette C, et al.
Lancet Respir Med
. 2024 Nov;
13(2):141-152.
PMID: 39486424
Background: Combined treatment with anti-PD-1 and anti-CTLA-4 antibodies has shown superiority over chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC), but data for older patients (aged ≥70 years) with...
2.
Spicer J, Garassino M, Wakelee H, Liberman M, Kato T, Tsuboi M, et al.
Lancet
. 2024 Sep;
404(10459):1240-1252.
PMID: 39288781
Background: At the first interim analysis of the KEYNOTE-671 trial, adding perioperative pembrolizumab to neoadjuvant chemotherapy significantly improved event-free survival in participants with early-stage non-small-cell lung cancer (NSCLC). We report...
3.
Jacob M, Fournel P, Tissot C, Cadranel J, Bylicki O, Monnet I, et al.
Lung Cancer
. 2024 Jul;
194:107868.
PMID: 39003937
Background: Management of stage-III-N2 non-small-cell lung cancer (NSCLC) based on a multimodal strategy (surgery or radiotherapycombined with systemic drugs) remains controversial. Patients are treated with a curative intent, and available...
4.
Bylicki O, Guisier F, Scherpereel A, Daniel C, Swalduz A, Grolleau E, et al.
Lung Cancer
. 2024 Jul;
194:107866.
PMID: 38972083
Background: First-line standard-of-care for unresectable, pleural mesothelioma (PM) changed with the phase 3 CheckMate 743 study results, showing that nivolumab plus ipilimumab (Nivo + Ipi) significantly extended overall survival (OS)...
5.
Amari L, Tomasini P, Dantony E, Rousseau-Bussac G, Ricordel C, Bigay-Game L, et al.
Lung Cancer
. 2024 Jun;
193:107843.
PMID: 38830303
Background: In an open-label multicenter non-randomized non-comparative phase II study in patients with stage IIIB/IV non-squamous non-small cell lung cancer (NSCLC), oncogenic addiction (EGFR mutation or ALK/ROS1 fusion), with disease...
6.
Auliac J, Thomas P, Bylicki O, Guisier F, Curcio H, AlainVegnenegre , et al.
Ther Adv Med Oncol
. 2024 Mar;
16:17588359241236451.
PMID: 38455711
Background: Few epidemiological data are available on surgically treated Caucasian patients with non-small-cell lung cancers (NSCLCs) harboring epidermal growth factor receptor () mutations. The main objective of this study was...
7.
Perisse A, Dao M, Butty D, Derkenne C, Charton F, Fabre N, et al.
Mil Med
. 2023 Dec;
189(9-10):2016-2022.
PMID: 38109715
Background: Smoking kills 8 million people a year worldwide. It is the most prevalent cause of death in France by cancer, cardiovascular, or respiratory diseases. Minimal advice consists in asking...
8.
Doubre H, Greillier L, Justeau G, Ricordel C, Swalduz A, Curcio H, et al.
J Cancer Res Clin Oncol
. 2023 Aug;
149(16):15095-15102.
PMID: 37626173
Background: Few data are available on the impact of venous thrombotic events (VTE) in patients with metastatic non-small cell lung cancer (mNSCLC) treated with immunotherapy. Methods: This is a secondary...
9.
Wakelee H, Liberman M, Kato T, Tsuboi M, Lee S, Gao S, et al.
N Engl J Med
. 2023 Jun;
389(6):491-503.
PMID: 37272513
Background: Among patients with resectable early-stage non-small-cell lung cancer (NSCLC), a perioperative approach that includes both neoadjuvant and adjuvant immune checkpoint inhibition may provide benefit beyond either approach alone. Methods:...
10.
Gendarme S, Zebachi S, Corre R, Greillier L, Justeau G, Bylicki O, et al.
J Geriatr Oncol
. 2023 May;
15(6):101506.
PMID: 37211514
Introduction: Predictors for mortality and toxicity in older patients with cancer are mainly studied in cohorts with various cancers at different stages. This study aims to identify predictive geriatric factors...